Stockscreener 앱 받기
28.85
0.65%
-0.19
전일 마감가:
$29.04
열려 있는:
$28.92
하루 거래량:
2.46M
Relative Volume:
2.61
시가총액:
$2.21B
수익:
$13.17M
순이익/손실:
$-199.06M
주가수익비율:
-10.53
EPS:
-2.74
순현금흐름:
$-156.53M
1주 성능:
-3.03%
1개월 성능:
-24.81%
6개월 성능:
-32.32%
1년 성능:
-26.10%
1일 변동 폭
$28.19
$29.25
1주일 범위
$28.19
$30.46
52주 변동 폭
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
XENE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
28.85 | 2.28B | 13.17M | -199.06M | -156.53M | -2.74 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-01-04 | 개시 | Citigroup | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 개시 | Goldman | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-10-19 | 개시 | Raymond James | Outperform |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2022-07-21 | 개시 | JP Morgan | Overweight |
| 2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-07-21 | 개시 | Needham | Buy |
| 2020-06-01 | 재개 | Jefferies | Buy |
| 2020-03-25 | 개시 | Wedbush | Outperform |
| 2020-01-08 | 개시 | William Blair | Outperform |
| 2019-09-20 | 개시 | Guggenheim | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2017-03-13 | 개시 | Jefferies | Buy |
| 2016-10-21 | 개시 | Stifel | Buy |
| 2016-09-26 | 개시 | Guggenheim | Buy |
| 2016-04-14 | 재확인 | Jefferies | Buy |
| 2015-10-30 | 재개 | Jefferies | Buy |
| 2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Xenon Pharmaceuticals Announces Equity Inducement Grants for New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Lis - GuruFocus
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals Awards $1.5M in Stock Options to 7 New Hires Under Nasdaq Rule - Stock Titan
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DE - Defense World
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - Defense World
Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
(XENE) Investment Analysis and Advice - news.stocktradersdaily.com
Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Xenon Pharmaceuticals’ SWOT analysis: neurological drug stock faces pivotal year - Investing.com India
Analysts Issue Forecasts for XENE FY2025 Earnings - Defense World
Leerink Partnrs Has Bullish Forecast for XENE Q2 Earnings - Defense World
XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World
What is William Blair’s Estimate for XENE FY2025 Earnings? - Defense World
HC Wainwright Issues Optimistic Outlook for XENE Earnings - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Evercore ISI - Defense World
How To Trade (XENE) - news.stocktradersdaily.com
Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Chardan Capital Reiterates “Buy” Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Needham & Company LLC Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00 - Defense World
Wells Fargo & Company Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Upgraded by StockNews.com - Defense World
Evercore ISI Group Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform Recommendation - Nasdaq
Xenon signals Phase 3 epilepsy readout in early 2026 with expanded pipeline advancements - MSN
Xenon Pharmaceuticals to Present at 2025 RBC Healthcare Conference - TipRanks
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times
XENE: Evercore ISI Group Initiates Coverage with 'Outperform' Ra - GuruFocus
XENE: Evercore ISI Group Initiates Coverage with 'Outperform' Rating | XENE Stock News - GuruFocus
Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday - Insider Monkey
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2025 Earnings Call Transcript - Insider Monkey
XENE: Wells Fargo Adjusts Price Target for Xenon Pharmaceuticals - GuruFocus
Xenon Pharmaceuticals (XENE) Price Target Adjusted by Analyst | - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down After Analyst Downgrade - Defense World
XENE: HC Wainwright Reiterates Buy Rating for Xenon Pharmaceuticals | XENE Stock News - GuruFocus
XENE: RBC Capital Adjusts Price Target as Xenon Pharmaceuticals Faces Timeline Shift | XENE Stock News - GuruFocus
XENE: Analyst Reaffirms Buy Rating with Price Target of $55 | XE - GuruFocus
XENE Price Target Revised Following Earnings and Data Delay | XE - GuruFocus
XENE: Needham Adjusts Price Target on Xenon Pharmaceuticals | XE - GuruFocus
XENE: RBC Capital Lowers Xenon Pharmaceuticals Price Target | XE - GuruFocus
FOS-tering patience: Xenon moves azetukalner data to next year - BioWorld MedTech
Xenon Pharmaceuticals stock falls on delayed study results By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals stock falls on delayed study results - Investing.com Australia
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlight - GuruFocus
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position and Promising Clinical Developments - GuruFocus
Xenon Pharmaceuticals Advances Clinical Programs Amid Financial Loss - TipRanks
Xenon Pharmaceuticals Reports Q1 2025 Results and Advances Clinical Pipeline - TipRanks
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xenon Pharmaceuticals Inc 주식 (XENE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Option Exercise |
17.76 |
22,468 |
399,032 |
53,770 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Option Exercise |
17.76 |
16,315 |
289,754 |
46,468 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Option Exercise |
17.76 |
16,217 |
288,014 |
47,519 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Sale |
40.20 |
22,468 |
903,214 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Sale |
40.50 |
16,315 |
660,806 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Sale |
40.08 |
16,217 |
649,977 |
31,302 |
1.89%
3.74%
자본화:
|
볼륨(24시간):